Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 5 of 6

  1. RO5024048

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  2. RO7034067

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  3. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  4. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  5. RO7204239, GYM329 Placebo

    Hoffmann-La Roche

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  6. RO7234292, RO7234292 Placebo

    Hoffmann-La Roche

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

  7. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  8. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  9. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderate to Severe Atopic Dermatitis (AD)

    phase 2 small molecule active

    1 trial

  10. RO7790121 placebo, RO7790121

    Hoffmann-La Roche

    Moderate to Severe Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  11. RO7790121, RO7790121 placebo/diluent

    Hoffmann-La Roche

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. Rozlytrek 200 mg hard capsules

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  13. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  15. WA39085

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  16. WA42985

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  17. WO39608

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  18. WO42178

    Hoffmann-La Roche

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  19. WO46063

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  20. bevacizumab [Avastin]

    Hoffmann-La Roche

    Liver Cancer

    phase 2 small molecule completed

    1 trial

  21. erlotinib [Tarceva]

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  22. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced solid tumors

    phase 1 other active

    1 trial

  23. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  24. BN44083

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  25. BO42203

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  26. BO45287

    Hoffmann-La Roche

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

  27. BP41628

    Hoffmann-La Roche

    Solid Tumors

    phase 1 other active

    1 trial

  28. BP42230

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  29. BP42233

    Hoffmann-La Roche

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  30. BP43015

    Hoffmann-La Roche

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  31. BP43131

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

    phase 1 other active

    1 trial

  32. BP44382

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  33. BP44551

    Hoffmann-La Roche

    Moderate to Severe Asthma

    phase 1 other active

    1 trial

  34. BP44956

    Hoffmann-La Roche

    Advanced and/or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  35. BP45211

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  36. BP45228

    Hoffmann-La Roche

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  37. BP45248

    Hoffmann-La Roche

    Not applicable

    phase 1 other active

    1 trial

  38. BP45325

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  39. BP45361

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  40. BP45378

    Hoffmann-La Roche

    Huntington’s Disease Gene Expansion Carriers

    phase 1 other active

    1 trial

  41. BP45669

    Hoffmann-La Roche

    Not Applicable (N/A)

    phase 1 other active

    1 trial

  42. BP45670

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  43. BP45800

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  44. BP45801

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  45. BP45910

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  46. BP45932

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  47. BP45980

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

    phase 1 other active

    1 trial

  48. BP46028

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.